MedPath

Dapagliflozin After Transcatheter Aortic Valve Implantation

Phase 4
Completed
Conditions
Aortic Stenosis
Transcatether Aortic Valve Implantation
Interventions
Registration Number
NCT04696185
Lead Sponsor
Spanish Society of Cardiology
Brief Summary

Pragmatic, controlled, prospective, randomized, open-label (open-label), evaluator-blind clinical trial (PROBE design) that will analyze the benefits of dapagliflozin treatment in patients with severe aortic stenosis discharged after implantation of an aortic valve prosthesis transcatheter (TAVI).

Detailed Description

Patients discharged after TAVI, with a history of heart failure (HF) plus depressed left ventricular ejection fraction (LVEF ≤ 40%) or diabetes mellitus (DM) or glomerular filtration rate (GFR) between 25 and 75 ml/min/1.73 m2, will be randomized (1:1) before hospital discharge to receive treatment with dapagliflozin 10 mg/day or no dapagliflozin (no placebo).

Only variables available during routine clinical practice will be collected and there will be no additional tests.

The incidence of clinical events and adherence to the dapagliflozin arm will be documented at 2 time-points (3 ± 1 months and 12 months) by phone calls and review of medical records.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1257
Inclusion Criteria
  • SEVERE AORTIC STENOSIS UNDERWENT TAVI

  • PRIOR HEART FAILURE ADMISSION AND ONE OF THE FOLLOWING CRITERIA:

    1. Left ventricular ejection fraction ≤ 40% or
    2. Diabetes mellitus or
    3. Estimated glomerular filtrate rate 25-75 ml/min/1.73 m2
Exclusion Criteria
  • Known allergy or intolerance to SGLT2 inhibitors.
  • Concomitant therapy with sulfonylurea or SGLT2 inhibitors..
  • Systolic blood pressure < 100 mmHg or diastolic blood pressure < 50 mmHg.
  • An estimated glomerular filtration rate (GFR) below 25 ml per minute per 1.73 m2.
  • Chronic cystitis and/or recurrent urinary tract infections (2 or more in the last year)
  • Poor control of diabetes mellitus that requires SGLT-2 inhibitor prescription on discharge according to treating physician judge.
  • Any medical condition that, in the investigator´s judgment, would seriously limit life expectancy (less than one year).
  • Pregnant or breast-feeding patients
  • Patients participating in other clinical trials.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
DapagliflozinDapagliflozin 10 MGSodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy with daily oral dose of dapagliflozin 10 mg
Primary Outcome Measures
NameTimeMethod
Incidence rate of the composite of all-cause mortality or worsening heart failure (HF)1 year

All-cause mortality and worsening HF (including hospitalization for HF or an urgent visit resulting in intravenous therapy for HF).

Secondary Outcome Measures
NameTimeMethod
Incidence rate of Cardiovascular death1 year

Mortality secondary to cardiovascular cause

Incidence rate all-cause mortality1 year

All cause mortality

Incidence rate of Hospitalization for Heart Failure1 year

Heart Failure requiring hospital admission

Incidence rate of Urgent Heart Failure visits1 year

Urgent Heart Failure visit requiring intravenous therapy

Incidence rate of the composite of Heart Failure hospitalization or Cardiovascular death1 year

Composite of Heart Failure hospitalization or Cardiovascular death

Total number of Heart Failure hospitalizations and Cardiovascular deaths1 year

Total number of (first and recurrent) Heart Failure hospitalizations and Cardiovascular deaths

Trial Locations

Locations (40)

Hospital General Universitario de Alicante

🇪🇸

Alicante, Spain

Hospital Universitario de Cruces

🇪🇸

Barakaldo, Spain

Hospital Universitario de Albacete

🇪🇸

Albacete, Spain

Centro Médico TEKNON

🇪🇸

Barcelona, Spain

Hospital Clinic

🇪🇸

Barcelona, Spain

Hospital de Bellvitge

🇪🇸

Barcelona, Spain

Hospital German I Trias

🇪🇸

Barcelona, Spain

Hospital Universitario Sant Pau

🇪🇸

Barcelona, Spain

Hospital Puerta Del Mar

🇪🇸

Cadiz, Spain

Hospital Virgen de Las Nieves

🇪🇸

Granada, Spain

Hospital Reina Sofia

🇪🇸

Cordoba, Spain

Hospital Juan Canalejo

🇪🇸

Coruña, Spain

Hospital San Cecilio

🇪🇸

Granada, Spain

Hospital Juan Ramón Jiménez

🇪🇸

Huelva, Spain

Hospital Universitario de Jaen

🇪🇸

Jaen, Spain

Hospital Universitario de León

🇪🇸

León, Spain

Clinica La Luz

🇪🇸

Madrid, Spain

Clinica Nuestra Señora de América de Madrid

🇪🇸

Madrid, Spain

Fundación Jimenez Diaz

🇪🇸

Madrid, Spain

Hospital 12 de Octubre

🇪🇸

Madrid, Spain

Hospital Clínico San Carlos

🇪🇸

Madrid, Spain

Hospital La Princesa

🇪🇸

Madrid, Spain

Hospital Puerta de Hierro

🇪🇸

Madrid, Spain

Hospital Ramón Y Cajal

🇪🇸

Madrid, Spain

Hospital Universitario de Torrejón

🇪🇸

Madrid, Spain

Hospital Virgen de La Victoria

🇪🇸

Málaga, Spain

Hospital Universitario Central de Asturias

🇪🇸

Oviedo, Spain

Hospital Son Espases

🇪🇸

Palma De Mallorca, Spain

Hospital Universitario de Navarra

🇪🇸

Pamplona, Spain

Hospital Universitario de Salamanca

🇪🇸

Salamanca, Spain

Hospital Marqués de Valdecilla

🇪🇸

Santander, Spain

Hospital Clínico de Santiago

🇪🇸

Santiago De Compostela, Spain

Hospital Virgen Del Rocio

🇪🇸

Sevilla, Spain

Hospital Universitario de Canarias

🇪🇸

Tenerife, Spain

Hospital Clínico de Valencia

🇪🇸

Valencia, Spain

Hospital La Fe

🇪🇸

Valencia, Spain

Hospital Clinico Universitario de Valladolid

🇪🇸

Valladolid, Spain

Hospital Álvaro Cunqueiro

🇪🇸

Vigo, Spain

Hospital Miguel Servet

🇪🇸

Zaragoza, Spain

Hospital Universitario Vall D´Hebron

🇪🇸

Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath